Literature DB >> 12620967

Transgenic rat model of Huntington's disease.

Stephan von Hörsten1, Ina Schmitt, Huu Phuc Nguyen, Carsten Holzmann, Thorsten Schmidt, Thomas Walther, Michael Bader, Reinhard Pabst, Philipp Kobbe, Jana Krotova, Detlef Stiller, Ants Kask, Annika Vaarmann, Silvia Rathke-Hartlieb, Jörg B Schulz, Ute Grasshoff, Ingrid Bauer, Ana Maria Menezes Vieira-Saecker, Martin Paul, Lesley Jones, Katrin S Lindenberg, Bernhard Landwehrmeyer, Andreas Bauer, Xiao-Jiang Li, Olaf Riess.   

Abstract

Huntington's disease (HD) is a late manifesting neurodegenerative disorder in humans caused by an expansion of a CAG trinucleotide repeat of more than 39 units in a gene of unknown function. Several mouse models have been reported which show rapid progression of a phenotype leading to death within 3-5 months (transgenic models) resembling the rare juvenile course of HD (Westphal variant) or which do not present with any symptoms (knock-in mice). Owing to the small size of the brain, mice are not suitable for repetitive in vivo imaging studies. Also, rapid progression of the disease in the transgenic models limits their usefulness for neurotransplantation. We therefore generated a rat model transgenic of HD, which carries a truncated huntingtin cDNA fragment with 51 CAG repeats under control of the native rat huntingtin promoter. This is the first transgenic rat model of a neurodegenerative disorder of the brain. These rats exhibit adult-onset neurological phenotypes with reduced anxiety, cognitive impairments, and slowly progressive motor dysfunction as well as typical histopathological alterations in the form of neuronal nuclear inclusions in the brain. As in HD patients, in vivo imaging demonstrates striatal shrinkage in magnetic resonance images and a reduced brain glucose metabolism in high-resolution fluor-deoxy-glucose positron emission tomography studies. This model allows longitudinal in vivo imaging studies and is therefore ideally suited for the evaluation of novel therapeutic approaches such as neurotransplantation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12620967     DOI: 10.1093/hmg/ddg075

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  101 in total

1.  Reduced expression of conditioned fear in the R6/2 mouse model of Huntington's disease is related to abnormal activity in prelimbic cortex.

Authors:  Adam G Walker; Jason R Ummel; George V Rebec
Journal:  Neurobiol Dis       Date:  2011-04-16       Impact factor: 5.996

Review 2.  Neurogenetics: single gene disorders.

Authors:  S-M Pulst
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-12       Impact factor: 10.154

Review 3.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

4.  Cortical Network Dynamics Is Altered in Mouse Models of Huntington's Disease.

Authors:  Elissa J Donzis; Ana María Estrada-Sánchez; Tim Indersmitten; Katerina Oikonomou; Conny H Tran; Catherine Wang; Shahrzad Latifi; Peyman Golshani; Carlos Cepeda; Michael S Levine
Journal:  Cereb Cortex       Date:  2020-04-14       Impact factor: 5.357

5.  Therapeutic application of neural stem cells and adult neurogenesis for neurodegenerative disorders: regeneration and beyond.

Authors:  Sarah E Latchney; Amelia J Eisch
Journal:  Eur J Neurodegener Dis       Date:  2012

Review 6.  Adult neurogenesis in neurodegenerative diseases.

Authors:  Beate Winner; Jürgen Winkler
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-04-01       Impact factor: 10.005

Review 7.  Techniques for brain imaging in vivo.

Authors:  Monica Garcia-Alloza; Brian J Bacskai
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

Review 8.  The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease.

Authors:  Ignacio Munoz-Sanjuan; Gillian P Bates
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

9.  Force-plate quantification of progressive behavioral deficits in the R6/2 mouse model of Huntington's disease.

Authors:  Stephen C Fowler; Benjamin R Miller; Thomas W Gaither; Michael A Johnson; George V Rebec
Journal:  Behav Brain Res       Date:  2009-03-28       Impact factor: 3.332

10.  Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease.

Authors:  Xavier Guitart; Jordi Bonaventura; William Rea; Marco Orrú; Lucrezia Cellai; Ilaria Dettori; Felicita Pedata; Marc Brugarolas; Antonio Cortés; Vicent Casadó; Ching-Pang Chang; Manikandan Narayanan; Yijuang Chern; Sergi Ferré
Journal:  Neurobiol Dis       Date:  2016-08-24       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.